Objective: to review the progress in the research of tyrosine kinase inhibitors in recent years.
目的：对近年来酪氨酸激酶抑制剂的研究进展作以综述。
The small molecule tyrosine kinase inhibitors may bring hope in the future for patient with EMS.
小分子酪氨酸激酶抑制剂为治疗EMS带来新的希望。
Secondary FLT3-TKD mutations are associated with treatment failure with tyrosine kinase inhibitors.
继发性FLT3 - TKD突变与酪氨酸激酶抑制剂治疗失败有关。
Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience.
大量的临床经验：酪氨酸激酶抑制剂治疗患有分化型甲状腺癌的患者：M。D。安德森经验。
The mechanisms, clinical applications of small-molecule tyrosine kinase inhibitors on brain metastasis and therapeutic choice after the failure will be reviewed in this article.
本文就小分子酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移的机理、临床应用以及治疗失败后的处理等方面作一综述。
With the success of small-molecule tyrosine kinase inhibitors in non-small cell lung cancer, recent clinical researches have shown their activities against brain and leptomeningeal metastases.
随着小分子酪氨酸激酶抑制剂在非小细胞肺癌治疗上获得成功，陆续有其治疗非小细胞肺癌脑转移及脑膜转移的研究。
CONCLUSION: CD117 can be regard as the related tumor antigen of MM, and may be a valuable marker in the use of tyrosine kinase selective inhibitors, which inhibit the signal conduct to the target.
结论CD 117可作为MM的肿瘤相关抗原，也可作为靶向信号转导抑制剂酪氨酸激酶选择性抑制剂应用的有价值的标志。
CONCLUSION: CD117 can be regard as the related tumor antigen of MM, and may be a valuable marker in the use of tyrosine kinase selective inhibitors, which inhibit the signal conduct to the target.
结论CD 117可作为MM的肿瘤相关抗原，也可作为靶向信号转导抑制剂酪氨酸激酶选择性抑制剂应用的有价值的标志。
应用推荐